Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer’s. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known.
Researchers believe that these new findings may be of significance to the development of new medications.
The accumulation of the protein amyloid beta in the brain is a sign of Alzheimer’s disease. Sufficiently large quantities cause plaque, which blocks the function of the nerve cells and thereby impair the patient’s memory and cognitive ability.
A small proportion of Alzheimer’s patients have a hereditary risk gene, which causes overproduction of amyloid beta in the brain.
In all other cases, the cause of the disease has so far been explained by the body’s lack of ability to break down and remove amyloid beta. However, these new findings provide a more nuanced picture, explains Niklas Mattsson, researcher at Lund University and specialist physician at Skåne University Hospital:
“In our study, we show that accumulation of amyloid in the brain is associated with high levels of specific amyloid peptides in the cerebrospinal fluid. This means that overproduction of amyloid beta may contribute to development of Alzheimer’s disease in some people, even if they do not carry the hereditary risk gene for Alzheimer’s.
The fact that the disease in these individuals can be attributed to both the overproduction of and problems in breaking down amyloid beta may be of significance to the future development of drugs and treatments.”
The study noted increased levels of amyloid beta in a large group of patients with no hereditary risk gene. More than 330 people from Sweden participated in the study, some of whom suffered from mild cognitive disorders (which may be an early sign of Alzheimer’s), while others were part of a control group of healthy individuals.
“We were surprised by the results. Our study emphasises that Alzheimer’s is probably a more heterogeneous disease than we previously believed”, continues Niklas Mattsson.
“The results are important because they increase the understanding of how Alzheimer’s disease arises. Our hope is that this and other similar studies can increase the possibilities of personalising treatments that slow down the disease in the future”, says Oskar Hansson, reader at Lund University and consultant at Skåne University Hospital.
However, further studies are needed to verify the results. Apart from the number of participants, the strengths of this study include the use of three different methods to achieve acurate measurement results: cerebrospinal fluid samples, the use of a so-called PET scanner, and genetic analysis.
A weakness of the study is that it does not include any measured observations of the brain tissue, which is often the case in studies of Alzheimer’s disease.
Niklas Mattsson et al.
Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
Nature Communications (2016). DOI: 10.1038/ncomms10918
Illustration: illuminated spots (red, yellow and green) indicate an accumulation of the protein beta-amyloid. The top row shows the brain of a patient diagnosed with Alzheimer’s disease. Bottom row shows a brain from a healthy person. There are always some nonspecific binding of color markers, hence the bright spots in the healthy person. Credit: Swedish Biofinder Study